Trial Profile
A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Acronyms ESSENTIAL
- 18 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2022 According to a Karyopharm Therapeutics media release, data presented at the upcoming American Society of Hematology (ASH) 2021 Annual Meeting and Exposition.
- 11 Dec 2021 Results presented in the Karyopharm Therapeutics Media Release.